CDNA Nasdaq Services-Medical Laboratories Financials FY2016βFY2025
CareDx, Inc. had $380M of revenue in fiscal 2025, up 13.8% on the year before. Over five years, revenue changed +14.6% a year on average.
Last close Β· Oct 23, 2026
$69.21
0.1%Hi! I read CareDx, Inc.βs latest annual report (fiscal 2025). Here is what stands out:
Good So-so Weak
Are sales growing?
+13.8%
Yes. Sales grew 13.8% last year.
Does it make a profit?
β5.6%
No. It lost money last year.
How healthy are the accounts?
4 / 7
Mixed. It passes 4 of 7 health tests.
How is the share priced?
33.4x
One share costs 33.4 times its yearly profit per share.
Rules of thumb on reported numbers. A starting point, not a recommendation.
Is it selling more, and how much does it keep?
In plain words: Every quarter, companies publish how much they sold and earned. These are the days CareDx, Inc. did it, and the next one. Share prices often move a lot on those days.
Next results
October 29, 2026
Thursday Β· in 4 days
| Date | Results for | Time | Source |
|---|---|---|---|
| Jul 30, 2026 | Q2 '26 | After the market closes | 8-K β |
| Apr 15, 2026 | Q1 '26 | Time not announced | 8-K β |
| Jan 12, 2026 | Q4 '25 | Before the market opens | 8-K β |
| Nov 4, 2025 | Q3 '25 | After the market closes | 8-K β |
| Aug 6, 2025 | Q2 '25 | After the market closes | 8-K β |
| Apr 30, 2025 | Q1 '25 | After the market closes | 8-K β |
| Jan 13, 2025 | Q4 '24 | Before the market opens | 8-K β |
| Oct 15, 2024 | Q3 '24 | Before the market opens | 8-K β |
From SEC filings: the results press release (8-K) or, without one, the quarterly or annual report.
KIRA Β· CareDx, Inc. had $380M of revenue in fiscal 2025, up 13.8% on the year before. Over five years, revenue changed +14.6% a year on average. Its operating margin was β8.1%, down 20.3Β pts: of every 100 in sales, about β8 is left after running the business.
In plain words: Revenue is all the money customers paid. The margins show how many cents of each dollar of sales are left over at each step: after making the product (gross), after running the business (operating) and after everything, tax included (net).
Revenue
Revenue
Margins, % of revenue
Margins, % of revenue
KIRA Β· CareDx, Inc. lost $21.4M in fiscal 2025.
Loss periods are shown in red.
In plain words: Net income is the profit left after every cost and tax. Earnings per share (EPS) splits that profit across every share, so it shows what one share earned.
Net income
Net income
Diluted EPS
Diluted EPS
How much cash comes in, and where does it go?
Cash from operations minus capital spending.
In plain words: Profit on paper is not the same as cash in the bank. Free cash flow is the cash left after paying to run and maintain the business: the money it can hand back to shareholders, save or invest.
Free cash flow
Free cash flow
Cash from operations vs capital spending
Cash from operations vs capital spending
KIRA Β· CareDx, Inc. returned $87.8M to shareholders in fiscal 2025. The diluted share count fell 5.9%.
In plain words: Companies hand cash back in two ways: dividends (cash paid to shareholders) and buybacks (buying back their own shares, so each remaining share owns a bigger slice).
Dividends and buybacks
Dividends and buybacks
Diluted shares outstanding (annual)
KIRA Β· No open-market insider trades in the last 12 months.
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. βPlanβ marks trades under a pre-arranged Rule 10b5-1 plan.
In plain words: Insiders are the people who run or own a big part of the company. Buying with their own money can signal confidence; selling often has personal reasons, like taxes or diversifying.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$0.0M
0 insiders
Of sales under plans
β
$0.0M
No open-market insider trades in the last 12 months.
Can it carry its debts, and how well does it use its money?
Cash, debt and the ratios that show how comfortably CareDx, Inc. can carry it.
In plain words: What the company owns and what it owes. More cash than debt is a cushion for bad times; a lot of debt leaves less room when business slows down.
Cash vs debt (incl. leases)
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | $348M | $293M | $235M | $261M | $177M |
| Current ratio | 5.6x | 5.1x | 4.0x | 3.9x | 2.9x |
| Quick ratio | 5.4x | 4.9x | 3.8x | 3.7x | 2.6x |
| Total assets | $567M | $543M | $467M | $491M | $413M |
| Total liabilities | $101M | $112M | $205M | $113M | $110M |
| Shareholders' equity | $466M | $431M | $261M | $378M | $303M |
| Net debt (β = net cash) | β | β | β | β | β |
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
In plain words: How much profit the business makes on the money put into it. A higher percentage means each dollar invested works harder.
Return on capital, equity and assets (annual)
KIRA Β· CareDx, Inc. passes 4 of 7 financial health tests (Piotroski F-score).
Nine pass/fail tests of profitability, funding and efficiency. 8β9 is strong, 0β2 weak.
In plain words: Nine yes/no tests of financial health, one point each. A green tick is a pass: 7 to 9 points is solid, 0 to 3 is weak.
| Test | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net income is positive | β | β | β | β | β | β | β | β | β | β |
| Cash from operations is positive | β | β | β | β | β | β | β | β | β | β |
| Return on assets rose | β | β | β | β | β | β | β | β | β | β |
| Cash from operations exceeds net income | β | β | β | β | β | β | β | β | β | β |
| Debt fell relative to assets | β | β | β | β | β | β | β | β | β | β |
| Current ratio rose | β | β | β | β | β | β | β | β | β | β |
| Share count didn't rise | β | β | β | β | β | β | β | β | β | β |
| Gross margin rose | β | β | β | β | β | β | β | β | β | β |
| Revenue rose relative to assets | β | β | β | β | β | β | β | β | β | β |
| F-score | β / 3 | 2 / 9 | 6 / 9 | 4 / 9 | 4 / 8 | 3 / 7 | 2 / 7 | 2 / 7 | 4 / 7 | 4 / 7 |
| Accruals ratio | β29.9% | β51.4% | β39.9% | β13.6% | β20.0% | β2.4% | β9.3% | β34.0% | 3.0% | β14.0% |
| Altman Z'' | β13.15 | β13.43 | β2.59 | β4.68 | 3.31 | 6.42 | 4.08 | β3.02 | 3.44 | 0.16 |
Every number, year by year.
Amounts in USD. Hover a ratioβs name for its definition.
In plain words: Every number we have, year by year. Download it as a spreadsheet if you want to dig deeper.
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | $40.6M | $48.3M | $76.6M | $127M | $192M | $296M | $322M | $280M | $334M | $380M |
| Net interest income | β$1.9M | β | β | β | β | β | β | β | β | β |
| Gross profit | $30.4M | $27.0M | $43.6M | $81.6M | β | β | β | β | β | β |
| Research and development | $12.4M | $12.4M | $14.5M | $30.7M | $48.9M | $76.5M | $90.4M | $82.4M | $72.5M | $71.4M |
| Operating income | β$37.3M | β$20.3M | β$15.6M | β$24.5M | β$22.5M | β$29.7M | β$77.2M | β$203M | $40.8M | β$30.8M |
| Pretax income | β$41.4M | β$57.3M | β$48.2M | β$23.9M | β$19.8M | β$32.1M | β$76.2M | β$190M | $52.9M | β$21.1M |
| Income tax | β$1.6M | β$1.7M | β$1.4M | β$2.0M | β$1.0M | β$1.4M | $0.4M | $0.1M | $0.3M | $0.3M |
| Net income | β$39.5M | β$55.5M | β$46.8M | β$22.0M | β$18.7M | β$30.7M | β$76.6M | β$190M | $52.5M | β$21.4M |
| Net income to common | β | β | β | β | β | β$30.7M | β$76.6M | β$190M | $52.5M | β$21.4M |
| Diluted EPS | β$2.39 | β$2.38 | β$1.31 | β$0.52 | β$0.40 | β$0.59 | β$1.44 | β$3.54 | $0.93 | β$0.40 |
| Diluted shares | 0.02B | 0.02B | 0.04B | 0.04B | 0.05B | 0.05B | 0.05B | 0.05B | 0.06B | 0.05B |
| Cash flow | ||||||||||
| Cash from operations | β$16.5M | β$14.3M | β$4.0M | β$2.8M | $33.4M | β$19.3M | β$25.2M | β$18.4M | $38.0M | $42.0M |
| Capital expenditure | $0.5M | $0.2M | $2.0M | β | β | β | β | β | β | β |
| Free cash flow | β$17.1M | β$14.5M | β$6.0M | β | β | β | β | β | β | β |
| Depreciation and amortization | $2.9M | $3.7M | $4.2M | $5.5M | $7.0M | $8.8M | $11.6M | $14.4M | $14.2M | $15.0M |
| Stock-based compensation | $2.0M | $1.7M | $7.1M | $22.4M | $23.4M | $36.1M | $46.6M | $49.1M | $66.4M | $34.9M |
| Acquisitions | $20.6M | β | β | $18.2M | $0.0M | $15.4M | $0.6M | $6.7M | $0.0M | $0.0M |
| Share buybacks | β | β | β | β | $0.0M | $0.0M | $0.6M | $27.5M | $0.5M | $87.8M |
| Dividends and buybacks | β | β | β | β | $0.0M | $0.0M | $0.6M | $27.5M | $0.5M | $87.8M |
| Balance sheet | ||||||||||
| Cash and short-term investments | $17.3M | $16.9M | $64.6M | $38.2M | $225M | $348M | $293M | $235M | $261M | $177M |
| Total debt | $23.9M | $34.1M | $0.0M | $0.0M | $0.0M | β | β | β | β | β |
| Current assets | $26.7M | $26.8M | $81.1M | $71.9M | $273M | $433M | $388M | $314M | $352M | $257M |
| Current liabilities | $40.8M | $42.9M | $19.5M | $34.8M | $69.2M | $77.3M | $76.0M | $78.1M | $89.4M | $89.8M |
| Inventory | $5.5M | $5.5M | $4.9M | $6.0M | $10.0M | $17.2M | $19.2M | $19.5M | $19.5M | $26.7M |
| Property and equipment, net | $2.9M | $2.1M | $4.1M | $4.4M | $10.7M | $22.0M | $35.5M | $35.2M | $33.6M | $33.0M |
| Goodwill | $13.8M | $12.0M | $12.0M | $23.9M | $23.9M | $37.0M | $37.5M | $40.3M | $40.3M | $40.3M |
| Intangible assets | $33.1M | $33.1M | $33.3M | $45.5M | $44.4M | $50.2M | $43.1M | $45.7M | $38.2M | $32.0M |
| Total assets | $76.7M | $83.6M | $131M | $152M | $369M | $567M | $543M | $467M | $491M | $413M |
| Total liabilities | $57.0M | $89.5M | $34.8M | $52.7M | $90.8M | $101M | $112M | $205M | $113M | $110M |
| Preferred stock | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M |
| Shareholders' equity | $19.5M | β$6.1M | $95.9M | $99.0M | $278M | $466M | $431M | $261M | $378M | $303M |
| Margins | ||||||||||
| Gross margin | 74.8% | 55.8% | 56.9% | 64.2% | β | β | β | β | β | β |
| Operating margin | β91.9% | β42.0% | β20.3% | β19.3% | β11.7% | β10.0% | β24.0% | β72.5% | 12.2% | β8.1% |
| EBITDA margin | β84.7% | β34.3% | β14.8% | β15.0% | β8.1% | β7.1% | β20.4% | β67.4% | 16.5% | β4.2% |
| Net margin | β97.1% | β114.8% | β61.1% | β17.3% | β9.7% | β10.3% | β23.8% | β67.9% | 15.7% | β5.6% |
| FCF margin | β42.0% | β30.0% | β7.9% | β | β | β | β | β | β | β |
| Net interest share of revenue | β4.6% | β | β | β | β | β | β | β | β | β |
| Returns | ||||||||||
| Return on capital | β112.7% | β145.4% | β39.3% | β31.9% | β33.6% | β | β | β | β | β |
| Return on capital employed | β104.0% | β49.9% | β14.0% | β21.0% | β7.5% | β6.1% | β16.5% | β52.3% | 10.1% | β9.5% |
| Return on equity | β202.6% | β831.1% | β104.1% | β22.5% | β9.9% | β8.2% | β17.1% | β55.0% | 16.4% | β6.3% |
| Return on assets | β51.4% | β69.2% | β43.6% | β15.6% | β7.2% | β6.6% | β13.8% | β37.7% | 11.0% | β4.7% |
| Return on tangible equity | β | β | β92.3% | β74.2% | β8.9% | β8.1% | β21.9% | β108.6% | 17.5% | β9.3% |
| Growth | ||||||||||
| Revenue growth | β | 18.9% | 58.4% | 66.0% | 51.3% | 54.2% | 8.6% | β12.9% | 19.1% | 13.8% |
| Net income growth | β | β | β | β | β | β | β | β | β | β140.6% |
| EPS growth | β | β | β | β | β | β | β | β | β | β143.0% |
| Share count change | β | 41.4% | 52.7% | 18.3% | 10.3% | 12.4% | 2.1% | 0.8% | 5.3% | β5.9% |
| Financial health | ||||||||||
| Debt / equity | 1.2x | β | 0.0x | 0.0x | 0.0x | β | β | β | β | β |
| Current ratio | 0.7x | 0.6x | 4.2x | 2.1x | 3.9x | 5.6x | 5.1x | 4.0x | 3.9x | 2.9x |
| Quick ratio | 0.5x | 0.5x | 3.9x | 1.9x | 3.8x | 5.4x | 4.9x | 3.8x | 3.7x | 2.6x |
| Capital allocation | ||||||||||
| Capex / revenue | 1.4% | 0.4% | 2.7% | β | β | β | β | β | β | β |
| Stock comp / revenue | 4.9% | 3.6% | 9.3% | 17.6% | 12.2% | 12.2% | 14.5% | 17.5% | 19.9% | 9.2% |
| Quality scores | ||||||||||
| Piotroski F-score | β | 2.0 | 6.0 | 4.0 | 4.0 | 3.0 | 2.0 | 2.0 | 4.0 | 4.0 |
| Altman Z'' | β13.2 | β13.4 | β2.6 | β4.7 | 3.3 | 6.4 | 4.1 | β3.0 | 3.4 | 0.2 |
| Accruals ratio | β29.9% | β51.4% | β39.9% | β13.6% | β20.0% | β2.4% | β9.3% | β34.0% | 3.0% | β14.0% |
Source: SEC EDGAR XBRL filings (CIK 0001217234). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only β not investment advice. Check the original filings before relying on any figure.
